A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Active:	Yes
Cancer Type:	Lung Cancer Lymphoma Neuroendocrine Tumor Ovarian Cancer	NCT ID:	NCT02922764
Trial Phases:	Phase I	Protocol IDs:	RGX-104-001 (primary) NCI-2017-00226
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Inspirna, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT02922764

Summary

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of
RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and
in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus
carboplatin/pemetrexed.

Objectives

RGX-104 activates LXR, resulting in depletion of both myeloid-derived suppressor cells
(MDSCs) as well as tumor blood vessels. MDSCs block the ability of T-cells and other cells of
the immune system from attacking tumors.

During the dose escalation stage, multiple doses and schedules of orally administered RGX-104
with or without nivolumab, ipilimumab, docetaxel, or pembrolizumab plus
carboplatin/pemetrexed (single agent or combination therapy) will be evaluated in patients
with advanced solid tumors and lymphoma (i.e., locally advanced and unresectable, or
metastatic) who have had progressive disease (PD) on available standard systemic therapies or
for which there are no standard systemic therapies of relevant impact. Dose escalation in
combination with pembrolizumab plus carboplatin/pemetrexed will be restricted to patients
with non-small cell lung cancer (NSCLC).

In the expansion stage of the study, additional patients with endometrial cancer, epithelial
ovarian carcinoma (EOC), NSCLC, or small cell lung cancer (SCLC)/high-grade neuroendocrine
tumors (HG-NET) will be treated at the MTD (or maximum tested dose if no MTD is identified,
or dose below the MTD if there is evidence suggesting a more favorable risk/benefit profile).
This stage will provide further characterization of the safety, efficacy, PK, and
pharmacodynamics, including biomarkers of immunologic activity and LXR target activation, of
RGX-104 as a single agent (EOC), in combination with docetaxel (SCLC/HG-NET), and and in
combination with pembrolizumab plus carboplatin/pemetrexed (NSCLC).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.